Flagship Pioneering unveiled its latest biotechnology startup on Thursday, a company aiming to map the progression of diseases and tailor medicines to stages of a patient’s journey.

旗舰先锋公司周四公布了其最新的生物技术初创公司，该公司旨在绘制疾病进展图，并根据患者的病程阶段定制药物。

Called

称为

Etiome

原因

, the biotech wants to take on a slew of medical conditions, from Parkinson’s disease and rheumatoid arthritis to the common liver condition known as metabolic dysfunction-associated steatohepatitis. It’s starting up with $50 million from Flagship, the biotech company creator that founded Moderna.

，这家生物技术公司希望应对一系列医疗状况，从帕金森病、类风湿性关节炎到常见的肝脏疾病，即代谢功能障碍相关脂肪性肝炎。该公司由创立了Moderna的生物技术公司创建者Flagship提供5000万美元启动资金。

Etiome’s

埃蒂奥姆的

name is a portmanteau of etiology — a disease’s origin — and the “omics” sciences that study types of biological molecules. The company was born out of an initiative within Flagship to develop preventive medicines. It’s using a type of AI technology and a trove of health data to closely analyze the various biological changes that occur as certain diseases take hold.

名字是疾病起源的“病因学”和研究各类生物分子的“组学”科学的混成词。这家企业诞生于旗舰内部的一项计划，旨在开发预防性药物。公司利用一种人工智能技术和大量的健康数据，仔细分析某些疾病发作时产生的各种生物变化。

It hopes to use this information to pinpoint markers of different disease “stages,” better understand which people are more likely to progress, and intervene with a medicine before they do.  .

它希望能够利用这些信息来精确定位不同疾病“阶段”的标志物，更好地了解哪些人更容易进展，并在他们进展之前用药物进行干预。

Without that detailed data, it can be hard for drugmakers to figure out why some medicines don’t work on certain people, and why disease moves faster in some but not others. Having it should “lead to a dramatic increase in probability of success of the drugs that we push forward,' said Etiome president and Flagship origination partner Scott Lipnick..

如果没有这些详细的数据，药物制造商很难弄清楚为什么某些药物对某些人不起作用，以及为什么疾病在某些人身上发展得更快而在其他人身上则不然。拥有这些数据应该“大大提高我们推进的药物成功的概率”，Etiome总裁兼Flagship创始合伙人斯科特·利普尼克表示。

In Parkinson’s, for example, Lipnick noted how there may be different molecular processes driving a person’s struggle to walk or control their brain, necessitating different therapeutic interventions. In metabolic dysfunction-associated steatohepatitis, or MASH, certain changes might underlie the progrssion from a fatty liver to inflammation and eventually cirrhosis. .

例如，在帕金森病中，利普尼克指出，可能有不同的分子过程导致患者行走困难或控制大脑的能力受阻，这就需要不同的治疗干预。在代谢功能障碍相关的脂肪性肝炎（MASH）中，某些变化可能是从脂肪肝发展为炎症并最终导致肝硬化的基础。

If Etiome can understand those changes and target them at the right time, “we know it’s not too late,” Lipnick said. “That’s when you actually need to make a difference.”

如果埃蒂奥梅能理解这些变化并在合适的时机针对它们采取行动，“我们知道还不算太晚，”利普尼克说。“这才是你真正需要做出改变的时候。”

Like many other Flagship startups, Etiome is launching with lofty ambitions.

像许多其他旗舰初创公司一样，Etiome 怀着远大的抱负启动。

The company aims to develop medicines that can slow, stop or even reverse a variety of conditions, though it hasn’t yet revealed specific drug programs or when human testing might begin.

该公司旨在开发能够减缓、阻止甚至逆转多种疾病的药物，但尚未透露具体的药物计划或人体试验可能开始的时间。

A tough funding climate has made it difficult for startups to pursue a journey like that, in turn heightening the importance of pharmaceutical partnerships. A Flagship initiative focused on fostering alliances for its portfolio companies has

严峻的融资环境使得初创公司难以追求这样的旅程，从而提高了制药合作的重要性。旗舰计划旨在为其投资组合公司促进联盟的举措已经

yielded

产生

several deals

几笔交易

over the last year or so, and Lipnick said such collaborations are “key.”

在过去的一年左右的时间里，利普尼克说这样的合作是“关键”。

“We are not going to do everything alone,” he said.

“我们不可能独自完成所有的事情，”他说。